A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jan 2013 Planned end date changed from 1 Oct 2007 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 02 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.